PHARMACOLOGICAL EVALUATION OF LEVETIRACETAM AS ADD-ON DRUG TO EITHER PHENYTOIN OR SODIUM VALPROATE IN PATIENTS OF GENERALIZED ONSET TONIC-CLONIC SEIZURES HAVING BREAKTHROUGH SEIZURES: A RANDOMIZED AND COMPARATIVE STUDY
DOI:
https://doi.org/10.22159/ajpcr.2023v16i9.47884Keywords:
Breakthrough seizures, Generalized onset tonic-clonic seizures, Phenytoin, Sodium valproate, LevetiracetamAbstract
Objective: Breakthrough seizures are sudden and unexpected seizures that occur in people with epilepsy who generally have good control over the symptoms. The present study is aimed to compare phenytoin plus levetiracetam versus sodium valproate plus levetiracetam to control breakthrough seizures.
Methods: A prospective, comparative study was carried out in Generalized onset tonic-clonic seizures (GTCS) patients with breakthrough seizures in Gajra Raja Medical College, Gwalior (M.P.) from February 2021 to August 2022. Participants were randomly allocated to 2 groups, namely phenytoin + levetiracetam (PL) (n=62) and sodium valproate + levetiracetam (SL) (n=61). Patients in group PL received phenytoin at the dose of 200 mg twice a day in adults, 5 mg/kg/day in two divided doses in children plus levetiracetam 500 mg twice a day in adults and 30 mg/kg/day in three divided doses in children. Patients in group SL received sodium valproate 600 mg 3 times a day in adults, 30 mg/kg/day in three divided doses in children plus levetiracetam 500 mg twice a day in adults and 30 mg/kg/day in three divided doses in children. The mean reduction in seizure frequency and patients response to the treatment in the last 30 days were recorded before the start of therapy and at 3 and 6 months after therapy. Adverse drug reactions were recorded during the study period. Statistical analysis was performed using (Statistical Package for the Social Sciences) software.
Results: Mean seizure frequency decreased by 59 and 85% in PL and by 59 and 91% in the SL group and is significant (p<0.05) from baseline value at 3 and 6 months, respectively, in both the groups. SL group showed significantly (p<0.05) better response, than PL group in controlling seizures at 6 months. Excellent response by patients was seen by 21% and 49% in PL and SL groups, respectively. Adverse effects noted during the study were mild, including somnolence, headache, dizziness, GIT stress, and fatigue, and responded to symptomatic treatment. Twenty-nine (29%) of PL cases and 6% of SL cases underwent fatigue as adverse drug reactions that showed better tolerability of the SL group.
Conclusion: Sodium valproate plus levetiracetam is more efficacious and safer than phenytoin plus levetiracetam in the management of breakthrough seizures in GTCS patients.
Downloads
References
Stafstrom CE, Carmant L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb Perspect Med 2015;5:a022426. doi: 10.1101/cshperspect.a022426, PMID 26033084
Egesa IJ, Newton CR, Kariuki SM. Evaluation of the international league against epilepsy 1981, 1989, and 2017 classifications of seizure semiology and etiology in a population-based cohort of children and adults with epilepsy. Epilepsia Open 2022;7:98-109. doi: 10.1002/ epi4.12562, PMID 34792291
Daniel HL. Seizure and epilepsy. In: Dan L, Dennis L, Kasper J, Jameson JL, Fauci AS, Stephen L, et al, editors. Harrison’s Principles of Internal Medicine. 20th ed. New York: McGrew-Hill; 2018.
Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Publications; 2021. doi 10.5005/jp/books/12021
Bonnett LJ, Powell GA, Tudur SC, Marson AG. Breakthrough seizures-further analysis of the standard versus new antiepileptic drugs (SANAD) study. PLoS One 2017;12:e0190035. doi: 10.1371/journal. pone.0190035, PMID 29267375
Kumar S. Factors precipitating breakthrough seizures in well-controlled epilepsy. Indian Pediatr 2005;42:182-3. PMID 15767720
Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-37. doi: 10.1111/j.1528-1157.1979.tb04857.x, PMID 499118
Cherian A, Thomas SV. Status epilepticus. Ann Indian Acad Neurol 2009;12:140-53. doi: 10.4103/0972-2327.56312, PMID 20174493
Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008;4:507-23. doi: 10.2147/ndt.s2937, PMID 18830435
Praveen AN, Panchaksharimath P, Nagaraj K. A comparative study to evaluate the efficacy and safety of levetiracetam as an add-on to carbamazepine and phenytoin in focal seizures at a tertiary care hospital. Biomed Pharmacol J 2020;13:383-90. doi: 10.13005/bpj/1898
Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 2022;3:CD011501. doi: 10.1002/14651858.CD011501.pub3, PMID 35285519
Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: Results from the national general practice study of epilepsy. Lancet 1995;346:140-4. doi: 10.1016/s0140- 6736(95)91208-8, PMID 7603228.
Pellock JM, Dodson WE, Bourgeois BF. Pediatric Epilepsy: Diagnosis and Therapy. 3rd ed. New York: Springer Publishing Company; 2008.
Swaroop HS, Ananya C, Nithin K, Jayashankar CA, Babu HS, Srinivas BN. Levetiracetam: A review of its use in the treatment of epilepsy. Int J Biomed Res 2013;2:166-72. doi: 10.14194/ijmbr.232
Sarhan EM, Walker MC, Selai C. Evidence for efficacy of combination of antiepileptic drugs in treatment of epilepsy. J Neurol Res 2016;4:267-76. doi: org/10.14740/jnr356w
Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: Alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008;8:345-52. doi: 10.1007/s11910-008- 0053-7, PMID 18590620
Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. Epilepsia 2009;50:387-97. doi: 10.1111/j.1528- 1167.2008.01713.x, PMID 18627416
Zhao J, Sang Y, Zhang Y, Zhang D, Chen J, Liu X. Efficacy of levetiracetam combined with sodium valproate on pediatric epilepsy and its effect on serum miR-106b in children. Exp Ther Med 2019;18:4436-42. doi: 10.3892/etm.2019.8098, PMID 31777547
Lambrechts DA, Sadzot B, van Paesschen W, van Leusden JA, Carpay J, Bourgeois P, et al. Efficacy and safety of levetiracetam in clinical practice: Results of the SKATE trial from Belgium and the Netherlands. Seizure 2006;15:434-42. doi: 10.1016/j.seizure.2006.05.013, PMID 16893660
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr Saroj kothari, vineet chaturvedi, ajay gupta, Dr Dinesh Udainiya
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.